News
06-07-2010, 04:22 AM
Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy...
More... (http://mnt.to/f/3Dzq)
More... (http://mnt.to/f/3Dzq)